Dyne Therapeutics (DYN) Competitors $13.15 -0.03 (-0.23%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$13.14 -0.01 (-0.04%) As of 07:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DYN vs. RVMD, GRFS, RYTM, LEGN, ABVX, RNA, CYTK, AXSM, NUVL, and TGTXShould you be buying Dyne Therapeutics stock or one of its competitors? The main competitors of Dyne Therapeutics include Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Legend Biotech (LEGN), Abivax (ABVX), Avidity Biosciences (RNA), Cytokinetics (CYTK), Axsome Therapeutics (AXSM), Nuvalent (NUVL), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Dyne Therapeutics vs. Its Competitors Revolution Medicines Grifols Rhythm Pharmaceuticals Legend Biotech Abivax Avidity Biosciences Cytokinetics Axsome Therapeutics Nuvalent TG Therapeutics Dyne Therapeutics (NASDAQ:DYN) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership. Do analysts prefer DYN or RVMD? Dyne Therapeutics currently has a consensus price target of $34.07, suggesting a potential upside of 159.06%. Revolution Medicines has a consensus price target of $73.67, suggesting a potential upside of 58.25%. Given Dyne Therapeutics' higher probable upside, equities analysts clearly believe Dyne Therapeutics is more favorable than Revolution Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyne Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 3 Strong Buy rating(s) 3.06Revolution Medicines 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 3.07 Do insiders and institutionals hold more shares of DYN or RVMD? 96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 20.8% of Dyne Therapeutics shares are held by company insiders. Comparatively, 8.2% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, DYN or RVMD? Dyne Therapeutics has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Is DYN or RVMD more profitable? Revolution Medicines' return on equity of -41.78% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dyne TherapeuticsN/A -64.12% -56.75% Revolution Medicines N/A -41.78%-35.63% Which has preferable valuation and earnings, DYN or RVMD? Dyne Therapeutics has higher earnings, but lower revenue than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDyne TherapeuticsN/AN/A-$317.42M-$3.86-3.41Revolution Medicines$11.58M751.43-$600.09M-$4.50-10.34 Does the media refer more to DYN or RVMD? In the previous week, Revolution Medicines had 36 more articles in the media than Dyne Therapeutics. MarketBeat recorded 45 mentions for Revolution Medicines and 9 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.26 beat Revolution Medicines' score of 0.46 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 13 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryDyne Therapeutics beats Revolution Medicines on 8 of the 15 factors compared between the two stocks. Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DYN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DYN vs. The Competition Export to ExcelMetricDyne TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.87B$2.54B$5.78B$10.18BDividend YieldN/A57.24%5.73%4.60%P/E Ratio-3.4123.6475.3926.02Price / SalesN/A545.33460.5891.38Price / CashN/A27.5625.8129.91Price / Book2.125.3812.836.25Net Income-$317.42M$32.95M$3.29B$270.76M7 Day Performance-1.13%1.21%0.85%2.54%1 Month Performance6.22%5.08%4.68%5.73%1 Year Performance-61.39%-1.67%70.14%25.85% Dyne Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DYNDyne Therapeutics3.9338 of 5 stars$13.15-0.2%$34.07+159.1%-61.4%$1.87BN/A-3.41100Positive NewsRVMDRevolution Medicines4.1878 of 5 stars$41.06+1.4%$72.00+75.4%+6.5%$7.57B$11.58M0.00250Trending NewsAnalyst ForecastAnalyst RevisionGRFSGrifols3.9865 of 5 stars$10.11-0.2%$10.30+1.9%+6.7%$6.96B$7.81B0.0023,822RYTMRhythm Pharmaceuticals3.2576 of 5 stars$99.77-2.3%$101.57+1.8%+93.9%$6.78B$130.13M0.00140Positive NewsLEGNLegend Biotech3.1964 of 5 stars$34.62-4.0%$74.22+114.4%-34.2%$6.66B$627.24M0.002,609Positive NewsABVXAbivax2.5629 of 5 stars$90.00+2.2%$92.33+2.6%+616.8%$6.65BN/A0.0061News CoverageEarnings ReportAnalyst ForecastShort Interest ↑Gap DownRNAAvidity Biosciences2.1094 of 5 stars$48.05-4.6%$67.00+39.4%+7.3%$6.48B$10.90M0.00190Trending NewsAnalyst ForecastGap UpCYTKCytokinetics4.3855 of 5 stars$52.09-1.7%$75.38+44.7%-8.5%$6.34B$18.47M0.00250Positive NewsAXSMAxsome Therapeutics4.915 of 5 stars$129.29+3.3%$177.86+37.6%+26.4%$6.25B$385.69M0.00380Positive NewsNUVLNuvalent3.1552 of 5 stars$79.83-1.3%$120.91+51.5%-8.0%$5.83BN/A0.0040Positive NewsInsider TradeTGTXTG Therapeutics4.3048 of 5 stars$32.38+0.5%$46.25+42.8%+35.5%$5.11B$329M87.05290Positive NewsInsider Trade Related Companies and Tools Related Companies Revolution Medicines Competitors Grifols Competitors Rhythm Pharmaceuticals Competitors Legend Biotech Competitors Abivax Competitors Avidity Biosciences Competitors Cytokinetics Competitors Axsome Therapeutics Competitors Nuvalent Competitors TG Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DYN) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DYN Stock Alerts